MA46228A - Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll - Google Patents
Inhibiteurs bicycliques fusionnés de l'interaction ménine-mllInfo
- Publication number
- MA46228A MA46228A MA046228A MA46228A MA46228A MA 46228 A MA46228 A MA 46228A MA 046228 A MA046228 A MA 046228A MA 46228 A MA46228 A MA 46228A MA 46228 A MA46228 A MA 46228A
- Authority
- MA
- Morocco
- Prior art keywords
- menin
- mll interaction
- bicyclic inhibitors
- fusion
- fusion bicyclic
- Prior art date
Links
- 230000004927 fusion Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000003993 interaction Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394291P | 2016-09-14 | 2016-09-14 | |
| EP16192424 | 2016-10-05 | ||
| EP17180228 | 2017-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46228A true MA46228A (fr) | 2019-07-24 |
Family
ID=59901513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046228A MA46228A (fr) | 2016-09-14 | 2017-09-13 | Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10611778B2 (de) |
| EP (1) | EP3512858B1 (de) |
| JP (1) | JP7033141B2 (de) |
| KR (1) | KR102493364B1 (de) |
| CN (1) | CN109715634B (de) |
| AU (1) | AU2017326485B2 (de) |
| CA (1) | CA3033020A1 (de) |
| ES (1) | ES2966316T3 (de) |
| IL (1) | IL265231B (de) |
| MA (1) | MA46228A (de) |
| MX (1) | MX389598B (de) |
| TW (1) | TWI753016B (de) |
| WO (1) | WO2018050684A1 (de) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016040330A1 (en) | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| AR104020A1 (es) | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
| WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| CN109152784B (zh) | 2016-03-16 | 2021-12-28 | 库拉肿瘤学公司 | 经取代的menin-mll抑制剂及使用方法 |
| CN109640987B (zh) | 2016-03-16 | 2022-12-02 | 库拉肿瘤学公司 | Menin-mll的桥联双环抑制剂及使用方法 |
| CN109689663B (zh) | 2016-09-14 | 2023-04-14 | 詹森药业有限公司 | Menin-mll相互作用的螺二环抑制剂 |
| MA46228A (fr) | 2016-09-14 | 2019-07-24 | Janssen Pharmaceutica Nv | Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| BR112019012106A2 (pt) | 2016-12-15 | 2019-10-29 | Janssen Pharmaceutica Nv | inibidores de azepano de interação menin-mill |
| CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| US11649251B2 (en) | 2017-09-20 | 2023-05-16 | Kura Oncology, Inc. | Substituted inhibitors of menin-MLL and methods of use |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| KR20200101389A (ko) | 2017-12-20 | 2020-08-27 | 얀센 파마슈티카 엔.브이. | 메닌-mll 상호작용의 엑소-아자 스피로 억제제 |
| US11325921B2 (en) | 2018-03-30 | 2022-05-10 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active crosslinked cyclic secondary amine derivative |
| CA3108449A1 (en) * | 2018-08-08 | 2020-02-13 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active bridged piperidine derivative |
| SG11202101085PA (en) * | 2018-08-27 | 2021-03-30 | Sumitomo Dainippon Pharma Co Ltd | Optically active azabicyclic derivative |
| AU2019395201A1 (en) | 2018-12-06 | 2021-05-20 | Daiichi Sankyo Company, Limited | Cycloalkane-1,3-diamine derivative |
| JP7554829B2 (ja) | 2019-12-19 | 2024-09-20 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換直鎖スピロ誘導体 |
| CN114516873A (zh) * | 2020-11-18 | 2022-05-20 | 苏州优理生物医药科技有限公司 | 一种螺环类化合物、包含其药物组合物及其应用 |
| CN117177744A (zh) | 2021-01-29 | 2023-12-05 | 塞迪拉治疗股份有限公司 | Cdk2抑制剂及其使用方法 |
| EP4334320A1 (de) | 2021-05-08 | 2024-03-13 | JANSSEN Pharmaceutica NV | Substituierte spiroderivate |
| MX2023013174A (es) | 2021-05-08 | 2023-11-30 | Janssen Pharmaceutica Nv | Derivados espiro sustituidos. |
| WO2022253167A1 (en) | 2021-06-01 | 2022-12-08 | Janssen Pharmaceutica Nv | SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES |
| CN117425659A (zh) | 2021-06-03 | 2024-01-19 | 詹森药业有限公司 | 哒嗪或被螺环胺取代的1,2,4-三嗪 |
| CA3220099A1 (en) | 2021-06-17 | 2022-12-22 | Wei Cai | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cance |
| MX2023015436A (es) * | 2021-06-26 | 2024-02-21 | Cedilla Therapeutics Inc | Inhibidores de cdk2 y metodos de uso de los mismos. |
| CN116903609A (zh) * | 2021-11-05 | 2023-10-20 | 上海优理惠生医药有限公司 | 一种化合物、包含其的药物组合物及其应用 |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| WO2003070739A1 (en) | 2002-02-19 | 2003-08-28 | Cv Therapeutics, Inc. | Partial and full agonists of a1 adenosine receptors |
| US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| CA2509406C (en) * | 2002-12-23 | 2012-07-03 | Janssen Pharmaceutica N.V. | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| US7612078B2 (en) * | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| EP1753428A4 (de) * | 2004-05-14 | 2010-09-15 | Abbott Lab | Kinasehemmer als therapeutische wirkstoffe |
| EP1856128A4 (de) * | 2005-01-19 | 2009-12-23 | Merck & Co Inc | Inhibitoren von mitotischem kinesin |
| TWI389913B (zh) * | 2008-09-08 | 2013-03-21 | Lg Life Sciences Ltd | 并合雜環化合物 |
| JP2011026305A (ja) * | 2009-06-24 | 2011-02-10 | Daiichi Sankyo Co Ltd | イミダゾールカルボニル化合物を含有する医薬組成物 |
| EP2473054B1 (de) * | 2009-09-04 | 2017-06-14 | The Regents of the University of Michigan | Zusammensetzungen und verfahren zur behandlung von leukämie |
| CA2819620A1 (en) | 2010-12-03 | 2012-06-21 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
| EP2646454B1 (de) | 2010-12-03 | 2015-07-08 | Epizyme, Inc. | 7-deazapurin-modulatoren der histonmethyltransferase und verwendungsverfahren dafür |
| WO2014035140A2 (en) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
| CN103664991B (zh) * | 2012-09-19 | 2016-12-28 | 中国科学院福建物质结构研究所 | 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途 |
| UA118548C2 (uk) | 2012-12-21 | 2019-02-11 | Епізайм, Інк. | Тетрагідро- та дигідроізохіноліни як інгібітори prmt5 та їх застосування |
| EP3406607A1 (de) | 2012-12-21 | 2018-11-28 | Epizyme, Inc. | Prmt5-inhibitoren mit einem dihydro- oder tetrahydroisochinolin und verwendungen davon |
| JP2016505000A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| KR20150130389A (ko) * | 2013-03-13 | 2015-11-23 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법 |
| US20170119769A1 (en) * | 2014-06-10 | 2017-05-04 | The Trustees Of The University Of Pennsylvania | Scaffolds for inhibitors of menin-mll interactions |
| WO2015200680A2 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2016040330A1 (en) * | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| WO2016081732A1 (en) * | 2014-11-19 | 2016-05-26 | Memorial Sloan-Kettering Cancer Center | Thienopyrimidines and uses thereof |
| JP6584521B2 (ja) | 2015-02-24 | 2019-10-02 | ファイザー・インク | 抗がん剤として有用な置換ヌクレオシド誘導体 |
| WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| AR104020A1 (es) | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
| TWI870767B (zh) | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| AU2016378579A1 (en) | 2015-12-22 | 2018-06-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-MLL interaction |
| CN109152784B (zh) | 2016-03-16 | 2021-12-28 | 库拉肿瘤学公司 | 经取代的menin-mll抑制剂及使用方法 |
| CN109640987B (zh) | 2016-03-16 | 2022-12-02 | 库拉肿瘤学公司 | Menin-mll的桥联双环抑制剂及使用方法 |
| WO2017192543A1 (en) | 2016-05-02 | 2017-11-09 | Regents Of The University Of Michigan | Piperidines as menin inhibitors |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| EP3805215A1 (de) | 2016-06-10 | 2021-04-14 | Vitae Pharmaceuticals, LLC | Inhibitoren der menin-mll-interaktion |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| MA46228A (fr) | 2016-09-14 | 2019-07-24 | Janssen Pharmaceutica Nv | Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll |
| CN109689663B (zh) * | 2016-09-14 | 2023-04-14 | 詹森药业有限公司 | Menin-mll相互作用的螺二环抑制剂 |
| CA3033239A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| US10899758B2 (en) | 2016-09-16 | 2021-01-26 | Vitae Pharmaceuticals, Llc | Inhibitors of the menin-MLL interaction |
| EA201991448A1 (ru) | 2017-01-06 | 2019-12-30 | Янссен Фармацевтика Нв | Азепановые ингибиторы взаимодействия менин-mll |
| CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
-
2017
- 2017-09-13 MA MA046228A patent/MA46228A/fr unknown
- 2017-09-13 JP JP2019535973A patent/JP7033141B2/ja active Active
- 2017-09-13 CN CN201780056197.2A patent/CN109715634B/zh active Active
- 2017-09-13 MX MX2019002959A patent/MX389598B/es unknown
- 2017-09-13 US US16/331,579 patent/US10611778B2/en active Active
- 2017-09-13 TW TW106131464A patent/TWI753016B/zh not_active IP Right Cessation
- 2017-09-13 WO PCT/EP2017/073001 patent/WO2018050684A1/en not_active Ceased
- 2017-09-13 EP EP17768750.6A patent/EP3512858B1/de active Active
- 2017-09-13 ES ES17768750T patent/ES2966316T3/es active Active
- 2017-09-13 AU AU2017326485A patent/AU2017326485B2/en not_active Ceased
- 2017-09-13 KR KR1020197007938A patent/KR102493364B1/ko active Active
- 2017-09-13 CA CA3033020A patent/CA3033020A1/en active Pending
-
2019
- 2019-03-07 IL IL265231A patent/IL265231B/en active IP Right Grant
-
2020
- 2020-02-13 US US16/789,707 patent/US10975100B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW201823249A (zh) | 2018-07-01 |
| US10975100B2 (en) | 2021-04-13 |
| EP3512858C0 (de) | 2023-11-08 |
| AU2017326485A1 (en) | 2019-02-21 |
| EP3512858B1 (de) | 2023-11-08 |
| AU2017326485B2 (en) | 2021-04-22 |
| MX2019002959A (es) | 2019-07-04 |
| EP3512858A1 (de) | 2019-07-24 |
| TWI753016B (zh) | 2022-01-21 |
| US10611778B2 (en) | 2020-04-07 |
| US20190218230A1 (en) | 2019-07-18 |
| KR20190046888A (ko) | 2019-05-07 |
| US20200172556A1 (en) | 2020-06-04 |
| KR102493364B1 (ko) | 2023-01-27 |
| CA3033020A1 (en) | 2018-03-22 |
| IL265231A (en) | 2019-05-30 |
| JP7033141B2 (ja) | 2022-03-09 |
| BR112019004764A2 (pt) | 2019-05-28 |
| IL265231B (en) | 2021-06-30 |
| CN109715634B (zh) | 2022-09-27 |
| CN109715634A (zh) | 2019-05-03 |
| JP2019530745A (ja) | 2019-10-24 |
| MX389598B (es) | 2025-03-11 |
| ES2966316T3 (es) | 2024-04-19 |
| WO2018050684A1 (en) | 2018-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46228A (fr) | Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll | |
| IL321844A (en) | Menin–MLL interaction inhibitors | |
| DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| MA47576A (fr) | Composés inhibiteurs d'oga bicyclique | |
| MA41551A (fr) | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 | |
| EP3518934A4 (de) | Inhibitoren der adenosin-5'-nukleotidase | |
| DK3507291T3 (da) | Kondenserede bicykliske sgc-stimulatorer | |
| MA46180A (fr) | Analogues de l'amyline | |
| FI20165061L (fi) | Aluksen itsenäinen käyttö | |
| EP3443094A4 (de) | Verfahren zur reduzierung der c9orf72-expression | |
| EP3514431A4 (de) | Gewinderohrverbindung | |
| MA51337A (fr) | Inhibiteurs spiro exo-aza de l'interaction ménine-mll | |
| EP3481814A4 (de) | Tetrahydronaphthyridinpentanamid-integrin-antagonisten | |
| EP3415146A4 (de) | Inhibitor der inflammasomaktivierung | |
| DK3432872T3 (da) | Eflornithin til anvendelse til behandling af temozolomid tilbagevendende/refraktær anaplastisk astrocytom | |
| EP3484854A4 (de) | Apoptoseinhibitoren | |
| EP3415524A4 (de) | INHIBITOR DER a-SYNUKLEIN-EXPRESSION | |
| ITUA20161599A1 (it) | Contenitore e procedimento per la realizzazione dello stesso | |
| EP3446828A4 (de) | Bearbeitungszentrum | |
| MA43764A (fr) | Inhibiteur monovalent de l'interaction hutnfr1 | |
| EP3534888A4 (de) | Substituierte bicyclische heteroaryl-allosterische modulatoren von nikotinischen acetylcholin-rezeptoren | |
| EP3443104A4 (de) | Florigenpfad-toolkit | |
| EP3363288A4 (de) | Zusammensetzung zur zerstörung von mikroalgen oder sphaerocarpus | |
| EP3331887A4 (de) | Benzodiazepine als bromdomänenhemmer | |
| IL259561B (en) | Methods of predicting progression of barrett's esophagus |